Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 500 entries
Sorted by: Best Match Show Resources per page
Correction to: Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis.

European journal of nuclear medicine and molecular imaging

Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD, Rominger A, Afshar-Oromieh A.
PMID: 33748876
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):3014-3016. doi: 10.1007/s00259-021-05300-8.

No abstract available.

Cite
Alberts IL, Seide SE, Mingels C, et al. Correction to: Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(9):3014-3016doi: 10.1007/s00259-021-05300-8.
Alberts, I. L., Seide, S. E., Mingels, C., Bohn, K. P., Shi, K., Zacho, H. D., Rominger, A., & Afshar-Oromieh, A. (2021). Correction to: Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. European journal of nuclear medicine and molecular imaging, 48(9), 3014-3016. https://doi.org/10.1007/s00259-021-05300-8
Alberts, Ian Leigh, et al. "Correction to: Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis." European journal of nuclear medicine and molecular imaging vol. 48,9 (2021): 3014-3016. doi: https://doi.org/10.1007/s00259-021-05300-8
Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD, Rominger A, Afshar-Oromieh A. Correction to: Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):3014-3016. doi: 10.1007/s00259-021-05300-8. PMID: 33748876; PMCID: PMC8496592.
Copy Download .nbib Format: NLM
Accurate detection of intracranial extension of jugulotympanic paraganglioma by [.

European journal of nuclear medicine and molecular imaging

Araghi ZJ, Ranjbar S, Paar M, Pirich C, Beheshti M.
PMID: 34378065
Eur J Nucl Med Mol Imaging. 2021 Aug 11; doi: 10.1007/s00259-021-05490-1. Epub 2021 Aug 11.

No abstract available.

Cite
Araghi ZJ, Ranjbar S, Paar M, et al. Accurate detection of intracranial extension of jugulotympanic paraganglioma by [. Eur J Nucl Med Mol Imaging. 2021;doi: 10.1007/s00259-021-05490-1.
Araghi, Z. J., Ranjbar, S., Paar, M., Pirich, C., & Beheshti, M. (2021). Accurate detection of intracranial extension of jugulotympanic paraganglioma by [. European journal of nuclear medicine and molecular imaging, . https://doi.org/10.1007/s00259-021-05490-1
Araghi, Zahra Jamshidi, et al. "Accurate detection of intracranial extension of jugulotympanic paraganglioma by [." European journal of nuclear medicine and molecular imaging vol. (2021). doi: https://doi.org/10.1007/s00259-021-05490-1
Araghi ZJ, Ranjbar S, Paar M, Pirich C, Beheshti M. Accurate detection of intracranial extension of jugulotympanic paraganglioma by [. Eur J Nucl Med Mol Imaging. 2021 Aug 11; doi: 10.1007/s00259-021-05490-1. Epub 2021 Aug 11. PMID: 34378065.
Copy Download .nbib Format: NLM
A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET.

European journal of nuclear medicine and molecular imaging

Etminani K, Soliman A, Davidsson A, Chang JR, Martínez-Sanchis B, Byttner S, Camacho V, Bauckneht M, Stegeran R, Ressner M, Agudelo-Cifuentes M, Chincarini A, Brendel M, Rominger A, Bruffaerts R, Vandenberghe R, Kramberger MG, Trost M, Nicastro N, Frisoni GB, Lemstra AW, van Berckel BNM, Pilotto A, Padovani A, Morbelli S, Aarsland D, Nobili F, Garibotto V, Ochoa-Figueroa M.
PMID: 34328531
Eur J Nucl Med Mol Imaging. 2021 Jul 30; doi: 10.1007/s00259-021-05483-0. Epub 2021 Jul 30.

PURPOSE: The purpose of this study is to develop and validate a 3D deep learning model that predicts the final clinical diagnosis of Alzheimer's disease (AD), dementia with Lewy bodies (DLB), mild cognitive impairment due to Alzheimer's disease (MCI-AD),...

Cite
Etminani K, Soliman A, Davidsson A, et al. A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2021;doi: 10.1007/s00259-021-05483-0.
Etminani, K., Soliman, A., Davidsson, A., Chang, J. R., Martínez-Sanchis, B., Byttner, S., Camacho, V., Bauckneht, M., Stegeran, R., Ressner, M., Agudelo-Cifuentes, M., Chincarini, A., Brendel, M., Rominger, A., Bruffaerts, R., Vandenberghe, R., Kramberger, M. G., Trost, M., Nicastro, N., Frisoni, G. B., Lemstra, A. W., van Berckel, B. N. M., Pilotto, A., Padovani, A., Morbelli, S., Aarsland, D., Nobili, F., Garibotto, V., & Ochoa-Figueroa, M. (2021). A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. European journal of nuclear medicine and molecular imaging, . https://doi.org/10.1007/s00259-021-05483-0
Etminani, Kobra, et al. "A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET." European journal of nuclear medicine and molecular imaging vol. (2021). doi: https://doi.org/10.1007/s00259-021-05483-0
Etminani K, Soliman A, Davidsson A, Chang JR, Martínez-Sanchis B, Byttner S, Camacho V, Bauckneht M, Stegeran R, Ressner M, Agudelo-Cifuentes M, Chincarini A, Brendel M, Rominger A, Bruffaerts R, Vandenberghe R, Kramberger MG, Trost M, Nicastro N, Frisoni GB, Lemstra AW, van Berckel BNM, Pilotto A, Padovani A, Morbelli S, Aarsland D, Nobili F, Garibotto V, Ochoa-Figueroa M. A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2021 Jul 30; doi: 10.1007/s00259-021-05483-0. Epub 2021 Jul 30. PMID: 34328531.
Copy Download .nbib Format: NLM
Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier.

European journal of nuclear medicine and molecular imaging

Kang SH, Kim J, Kim JP, Cho SH, Choe YS, Jang H, Kim HJ, Koh SB, Na DL, Seong JK, Seo SW.
PMID: 34328533
Eur J Nucl Med Mol Imaging. 2021 Jul 30; doi: 10.1007/s00259-021-05499-6. Epub 2021 Jul 30.

PURPOSE: In this study, we used machine learning to develop a new method derived from a ligand-independent amyloid (Aβ) positron emission tomography (PET) classifier to harmonise different Aβ ligands.METHODS: We obtained 107 paired RESULTS: This classifier achieved high classification...

Cite
Kang SH, Kim J, Kim JP, et al. Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier. Eur J Nucl Med Mol Imaging. 2021;doi: 10.1007/s00259-021-05499-6.
Kang, S. H., Kim, J., Kim, J. P., Cho, S. H., Choe, Y. S., Jang, H., Kim, H. J., Koh, S. B., Na, D. L., Seong, J. K., & Seo, S. W. (2021). Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier. European journal of nuclear medicine and molecular imaging, . https://doi.org/10.1007/s00259-021-05499-6
Kang, Sung Hoon, et al. "Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier." European journal of nuclear medicine and molecular imaging vol. (2021). doi: https://doi.org/10.1007/s00259-021-05499-6
Kang SH, Kim J, Kim JP, Cho SH, Choe YS, Jang H, Kim HJ, Koh SB, Na DL, Seong JK, Seo SW. Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier. Eur J Nucl Med Mol Imaging. 2021 Jul 30; doi: 10.1007/s00259-021-05499-6. Epub 2021 Jul 30. PMID: 34328533.
Copy Download .nbib Format: NLM
Prognostic value of regional myocardial flow reserve derived from .

European journal of nuclear medicine and molecular imaging

von Felten E, Benz DC, Benetos G, Baehler J, Patriki D, Rampidis GP, Giannopoulos AA, Bakula A, Gräni C, Pazhenkottil AP, Gebhard C, Fuchs TA, Kaufmann PA, Buechel RR.
PMID: 34191100
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):311-320. doi: 10.1007/s00259-021-05459-0. Epub 2021 Jun 30.

PURPOSE: To assess the prognostic value of regional quantitative myocardial flow measures as assessed by METHODS: We retrospectively included 150 consecutive patients with suspected CAD who underwent clinically indicated 13 N-ammonia PET-MPI and who did not undergo revascularization within...

Cite
von Felten E, Benz DC, Benetos G, et al. Prognostic value of regional myocardial flow reserve derived from . Eur J Nucl Med Mol Imaging. 2021;49(1):311-320doi: 10.1007/s00259-021-05459-0.
von Felten, E., Benz, D. C., Benetos, G., Baehler, J., Patriki, D., Rampidis, G. P., Giannopoulos, A. A., Bakula, A., Gräni, C., Pazhenkottil, A. P., Gebhard, C., Fuchs, T. A., Kaufmann, P. A., & Buechel, R. R. (2021). Prognostic value of regional myocardial flow reserve derived from . European journal of nuclear medicine and molecular imaging, 49(1), 311-320. https://doi.org/10.1007/s00259-021-05459-0
von Felten, Elia, et al. "Prognostic value of regional myocardial flow reserve derived from ." European journal of nuclear medicine and molecular imaging vol. 49,1 (2021): 311-320. doi: https://doi.org/10.1007/s00259-021-05459-0
von Felten E, Benz DC, Benetos G, Baehler J, Patriki D, Rampidis GP, Giannopoulos AA, Bakula A, Gräni C, Pazhenkottil AP, Gebhard C, Fuchs TA, Kaufmann PA, Buechel RR. Prognostic value of regional myocardial flow reserve derived from . Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):311-320. doi: 10.1007/s00259-021-05459-0. Epub 2021 Jun 30. PMID: 34191100; PMCID: PMC8712296.
Copy Download .nbib Format: NLM
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics.

European journal of nuclear medicine and molecular imaging

Kesch C, Yirga L, Dendl K, Handke A, Darr C, Krafft U, Radtke JP, Tschirdewahn S, Szarvas T, Fazli L, Gleave M, Giesel FL, Haberkorn U, Hadaschik B.
PMID: 34226953
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):385-389. doi: 10.1007/s00259-021-05423-y. Epub 2021 Jul 05.

PURPOSE: To evaluate fibroblast-activation-protein (FAP) expression in different clinical stages of prostate cancer (PC) with regards to utility of [METHODS: Tissue microarrays (TMAs) were constructed from prostatic tissue from 94 patients at different stages of PC (primary PC, patients...

Cite
Kesch C, Yirga L, Dendl K, et al. High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. Eur J Nucl Med Mol Imaging. 2021;49(1):385-389doi: 10.1007/s00259-021-05423-y.
Kesch, C., Yirga, L., Dendl, K., Handke, A., Darr, C., Krafft, U., Radtke, J. P., Tschirdewahn, S., Szarvas, T., Fazli, L., Gleave, M., Giesel, F. L., Haberkorn, U., & Hadaschik, B. (2021). High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. European journal of nuclear medicine and molecular imaging, 49(1), 385-389. https://doi.org/10.1007/s00259-021-05423-y
Kesch, Claudia, et al. "High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics." European journal of nuclear medicine and molecular imaging vol. 49,1 (2021): 385-389. doi: https://doi.org/10.1007/s00259-021-05423-y
Kesch C, Yirga L, Dendl K, Handke A, Darr C, Krafft U, Radtke JP, Tschirdewahn S, Szarvas T, Fazli L, Gleave M, Giesel FL, Haberkorn U, Hadaschik B. High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):385-389. doi: 10.1007/s00259-021-05423-y. Epub 2021 Jul 05. PMID: 34226953; PMCID: PMC8712308.
Copy Download .nbib Format: NLM
Correction to: Machine learning based on clinico-biological features integrated 18F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung.

European journal of nuclear medicine and molecular imaging

Ren C, Zhang J, Qi M, Zhang J, Zhang Y, Song S, Sun Y, Cheng J.
PMID: 33532911
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1696. doi: 10.1007/s00259-021-05226-1.

No abstract available.

Cite
Ren C, Zhang J, Qi M, et al. Correction to: Machine learning based on clinico-biological features integrated 18F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung. Eur J Nucl Med Mol Imaging. 2021;48(5):1696doi: 10.1007/s00259-021-05226-1.
Ren, C., Zhang, J., Qi, M., Zhang, J., Zhang, Y., Song, S., Sun, Y., & Cheng, J. (2021). Correction to: Machine learning based on clinico-biological features integrated 18F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung. European journal of nuclear medicine and molecular imaging, 48(5), 1696. https://doi.org/10.1007/s00259-021-05226-1
Ren, Caiyue, et al. "Correction to: Machine learning based on clinico-biological features integrated 18F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung." European journal of nuclear medicine and molecular imaging vol. 48,5 (2021): 1696. doi: https://doi.org/10.1007/s00259-021-05226-1
Ren C, Zhang J, Qi M, Zhang J, Zhang Y, Song S, Sun Y, Cheng J. Correction to: Machine learning based on clinico-biological features integrated 18F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1696. doi: 10.1007/s00259-021-05226-1. PMID: 33532911; PMCID: PMC8182867.
Copy Download .nbib Format: NLM
Current status and future perspective of radiopharmaceuticals in China.

European journal of nuclear medicine and molecular imaging

Hu J, Li H, Sui Y, Du J.
PMID: 34767047
Eur J Nucl Med Mol Imaging. 2021 Nov 12; doi: 10.1007/s00259-021-05615-6. Epub 2021 Nov 12.

Radiopharmaceuticals are essential components of nuclear medicine and serve as one of the cornerstones of molecular imaging and precision medicine. They provide new means and approaches for early diagnosis and treatment of diseases. After decades of development and hard...

Cite
Hu J, Li H, Sui Y, et al. Current status and future perspective of radiopharmaceuticals in China. Eur J Nucl Med Mol Imaging. 2021;doi: 10.1007/s00259-021-05615-6.
Hu, J., Li, H., Sui, Y., & Du, J. (2021). Current status and future perspective of radiopharmaceuticals in China. European journal of nuclear medicine and molecular imaging, . https://doi.org/10.1007/s00259-021-05615-6
Hu, Ji, et al. "Current status and future perspective of radiopharmaceuticals in China." European journal of nuclear medicine and molecular imaging vol. (2021). doi: https://doi.org/10.1007/s00259-021-05615-6
Hu J, Li H, Sui Y, Du J. Current status and future perspective of radiopharmaceuticals in China. Eur J Nucl Med Mol Imaging. 2021 Nov 12; doi: 10.1007/s00259-021-05615-6. Epub 2021 Nov 12. PMID: 34767047; PMCID: PMC8586637.
Copy Download .nbib Format: NLM
Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson's disease (PD) do not overlap.

European journal of nuclear medicine and molecular imaging

Morbelli S, Chiola S, Donegani MI, Arnaldi D, Pardini M, Mancini R, Lanfranchi F, D'amico F, Bauckneht M, Miceli A, Biassoni E, Orso B, Barisione E, Benedetti L, Gianmario S, Nobili F.
PMID: 34984501
Eur J Nucl Med Mol Imaging. 2022 Jan 05; doi: 10.1007/s00259-021-05666-9. Epub 2022 Jan 05.

PURPOSE: Hyposmia is a common feature of COVID-19 and Parkinson's disease (PD). As parkinsonism has been reported after COVID-19, a link has been hypothesized between SARS-CoV2 infection and PD. We aimed to evaluate brain metabolic correlates of isolated persistent...

Cite
Morbelli S, Chiola S, Donegani MI, et al. Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson's disease (PD) do not overlap. Eur J Nucl Med Mol Imaging. 2022;doi: 10.1007/s00259-021-05666-9.
Morbelli, S., Chiola, S., Donegani, M. I., Arnaldi, D., Pardini, M., Mancini, R., Lanfranchi, F., D'amico, F., Bauckneht, M., Miceli, A., Biassoni, E., Orso, B., Barisione, E., Benedetti, L., Gianmario, S., & Nobili, F. (2022). Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson's disease (PD) do not overlap. European journal of nuclear medicine and molecular imaging, . https://doi.org/10.1007/s00259-021-05666-9
Morbelli, Silvia, et al. "Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson's disease (PD) do not overlap." European journal of nuclear medicine and molecular imaging vol. (2022). doi: https://doi.org/10.1007/s00259-021-05666-9
Morbelli S, Chiola S, Donegani MI, Arnaldi D, Pardini M, Mancini R, Lanfranchi F, D'amico F, Bauckneht M, Miceli A, Biassoni E, Orso B, Barisione E, Benedetti L, Gianmario S, Nobili F. Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson's disease (PD) do not overlap. Eur J Nucl Med Mol Imaging. 2022 Jan 05; doi: 10.1007/s00259-021-05666-9. Epub 2022 Jan 05. PMID: 34984501.
Copy Download .nbib Format: NLM
Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain.

European journal of nuclear medicine and molecular imaging

Wimberley C, Lavisse S, Hillmer A, Hinz R, Turkheimer F, Zanotti-Fregonara P.
PMID: 33693967
Eur J Nucl Med Mol Imaging. 2021 Mar 11; doi: 10.1007/s00259-021-05248-9. Epub 2021 Mar 11.

PURPOSE: Translocator protein 18-kDa (TSPO) imaging with positron emission tomography (PET) is widely used in research studies of brain diseases that have a neuro-immune component. Quantification of TSPO PET images, however, is associated with several challenges, such as the...

Cite
Wimberley C, Lavisse S, Hillmer A, et al. Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain. Eur J Nucl Med Mol Imaging. 2021;doi: 10.1007/s00259-021-05248-9.
Wimberley, C., Lavisse, S., Hillmer, A., Hinz, R., Turkheimer, F., & Zanotti-Fregonara, P. (2021). Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain. European journal of nuclear medicine and molecular imaging, . https://doi.org/10.1007/s00259-021-05248-9
Wimberley, Catriona, et al. "Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain." European journal of nuclear medicine and molecular imaging vol. (2021). doi: https://doi.org/10.1007/s00259-021-05248-9
Wimberley C, Lavisse S, Hillmer A, Hinz R, Turkheimer F, Zanotti-Fregonara P. Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain. Eur J Nucl Med Mol Imaging. 2021 Mar 11; doi: 10.1007/s00259-021-05248-9. Epub 2021 Mar 11. PMID: 33693967.
Copy Download .nbib Format: NLM
Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate.

European journal of nuclear medicine and molecular imaging

Gnanasegaran G, Paez D, Sathekge M, Giammarile F, Fanti S, Chiti A, Bom H, Vinjamuri S, Pascual TN, Bomanji J.
PMID: 33661327
Eur J Nucl Med Mol Imaging. 2021 Mar 04; doi: 10.1007/s00259-021-05241-2. Epub 2021 Mar 04.

No abstract available.

Cite
Gnanasegaran G, Paez D, Sathekge M, et al. Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate. Eur J Nucl Med Mol Imaging. 2021;doi: 10.1007/s00259-021-05241-2.
Gnanasegaran, G., Paez, D., Sathekge, M., Giammarile, F., Fanti, S., Chiti, A., Bom, H., Vinjamuri, S., Pascual, T. N., & Bomanji, J. (2021). Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate. European journal of nuclear medicine and molecular imaging, . https://doi.org/10.1007/s00259-021-05241-2
Gnanasegaran, Gopinath, et al. "Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate." European journal of nuclear medicine and molecular imaging vol. (2021). doi: https://doi.org/10.1007/s00259-021-05241-2
Gnanasegaran G, Paez D, Sathekge M, Giammarile F, Fanti S, Chiti A, Bom H, Vinjamuri S, Pascual TN, Bomanji J. Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate. Eur J Nucl Med Mol Imaging. 2021 Mar 04; doi: 10.1007/s00259-021-05241-2. Epub 2021 Mar 04. PMID: 33661327; PMCID: PMC7930105.
Copy Download .nbib Format: NLM
The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study.

European journal of nuclear medicine and molecular imaging

Caldarella C, Cocciolillo F, Taralli S, Lorusso M, Scolozzi V, Pizzuto DA, Calcagni ML, Rufini V, Guido D, Palluzzi F, Giacò L, Giordano A, Leccisotti L.
PMID: 34877609
Eur J Nucl Med Mol Imaging. 2021 Dec 08; doi: 10.1007/s00259-021-05629-0. Epub 2021 Dec 08.

PURPOSE: To investigate whether the COVID-19 pandemic and national lockdown had an impact on the extent of cancer disease at FDG PET/CT staging as surrogate marker.METHODS: Retrospective observational study including cancer patients submitted to FDG PET/CT staging from June...

Cite
Caldarella C, Cocciolillo F, Taralli S, et al. The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study. Eur J Nucl Med Mol Imaging. 2021;doi: 10.1007/s00259-021-05629-0.
Caldarella, C., Cocciolillo, F., Taralli, S., Lorusso, M., Scolozzi, V., Pizzuto, D. A., Calcagni, M. L., Rufini, V., Guido, D., Palluzzi, F., Giacò, L., Giordano, A., & Leccisotti, L. (2021). The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study. European journal of nuclear medicine and molecular imaging, . https://doi.org/10.1007/s00259-021-05629-0
Caldarella, Carmelo, et al. "The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study." European journal of nuclear medicine and molecular imaging vol. (2021). doi: https://doi.org/10.1007/s00259-021-05629-0
Caldarella C, Cocciolillo F, Taralli S, Lorusso M, Scolozzi V, Pizzuto DA, Calcagni ML, Rufini V, Guido D, Palluzzi F, Giacò L, Giordano A, Leccisotti L. The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study. Eur J Nucl Med Mol Imaging. 2021 Dec 08; doi: 10.1007/s00259-021-05629-0. Epub 2021 Dec 08. PMID: 34877609; PMCID: PMC8651274.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 500 entries